Home › Burkitt Lymphoma › Washington
Burkitt Lymphoma clinical trials in Washington
12 studies for Burkitt Lymphoma are looking for participants at sites in Washington.
Cities in Washington
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
RecruitingPhase 2
366 Days – 46 Years · All sexes · Updated Sep 28, 2026 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
RecruitingPhase 2
365 Days · All sexes · Updated Sep 25, 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07648264Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Medical Center-First Hill, Seattle
RecruitingPhase 3
Ages 18 to 39 · All sexes · Updated Sep 2, 2026 · NCT03150693A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
- and 1 more
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Sep 1, 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Recruiting
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT06710418Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2Healthy volunteers welcome
6 Months · All sexes · Updated May 29, 2026 · NCT04195633Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 23, 2026 · NCT07097363Study of SGR-1505 in Mature B-Cell Neoplasms
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2025 · NCT04260022Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 15, 2024 · NCT06034275From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.